<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026662</url>
  </required_header>
  <id_info>
    <org_study_id>eMatrixCO2 Preab</org_study_id>
    <nct_id>NCT01026662</nct_id>
  </id_info>
  <brief_title>In-vivo Analysis of a Fractional CO2 Laser System (eMatrixCO2) Intended for Treatment of Soft Tissue</brief_title>
  <acronym>eMatrixCO2</acronym>
  <official_title>In-vivo Analysis of a Fractional CO2 Laser System (eMatrixCO2) Intended for Treatment of Soft Tissue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syneron Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syneron Medical</source>
  <brief_summary>
    <textblock>
      This study will:&#xD;
&#xD;
      Evaluate the in vivo effects of treatment with eMatrixCO2 and to determine the dynamics of&#xD;
      their development over time following treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Histological and molecular assessment of tissue taken following treatment with different parameters and at various time points</measure>
    <time_frame>Immediate, 1, 3, 10, 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Record number and type of any AE during the study</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Abdominoplasty</condition>
  <arm_group>
    <arm_group_label>Abdominoplasty</arm_group_label>
    <description>Subjects scheduled for abdominoplasty surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation and skin resurfacing</intervention_name>
    <description>Subjects will receive treatment on the abdomen at different timepoints prior to a scheduled abdominoplasty. Following tissues excision samples of the treated tissue will be taken for analysis.</description>
    <arm_group_label>Abdominoplasty</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>eMatrixCO2</intervention_name>
    <arm_group_label>Abdominoplasty</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Abdominal Skin tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy Subjects scheduled for an abdominoplasty surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent agreement signed by the subject.&#xD;
&#xD;
          -  Healthy males or females older than 21 to 60 years of age.&#xD;
&#xD;
          -  Fitzpatrick skin type I-V (Although the systems are cleared for all skin types I-VI,&#xD;
             it is recommended to use the Matrix applicators on skin types I - V).&#xD;
&#xD;
          -  Willingness to follow the treatment and follow-up schedule and the post-treatment&#xD;
             care.&#xD;
&#xD;
          -  For female candidates - post-menopausal or surgically sterilized, or using a medically&#xD;
             acceptable form of birth control at least 3 months prior to enrollment and during the&#xD;
             entire course of the study (i.e., oral contraceptives, IUD, contraceptive implant,&#xD;
             barrier methods with spermicide, or abstinence).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and/or breastfeeding.&#xD;
&#xD;
          -  Having a history of diseases stimulated by heat, such as recurrent Herpes&#xD;
&#xD;
          -  Simplex in the treated area, unless treatment is conducted following a prophylactic&#xD;
             regimen.&#xD;
&#xD;
          -  Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing&#xD;
             agents) one week before and after each treatment session.&#xD;
&#xD;
          -  Use of retinoids, antioxidants or therapeutic skin nourishing supplements at medicinal&#xD;
             concentration within 2 months of treatment or during the study and oral retinoids&#xD;
             within 6 months of the study.&#xD;
&#xD;
          -  Having received treatment with light, RF or other devices in the treated area within 6&#xD;
             months of treatment or during the study.&#xD;
&#xD;
          -  Having received collagen/fat injections or other methods of augmentation with injected&#xD;
             or implanted material in the treated area within 9 months of treatment or during the&#xD;
             study.&#xD;
&#xD;
          -  Having received Botox in the treated area within 6 months of treatment or during the&#xD;
             study.&#xD;
&#xD;
          -  Having undergone any other surgery in the treated area within 6 months of treatment&#xD;
             (or more if skin has not healed completely) or during the study.&#xD;
&#xD;
          -  History of keloid scarring or of abnormal wound healing.&#xD;
&#xD;
          -  Suffering from current or history of significant skin conditions in the treated area&#xD;
             or inflammatory skin conditions, including, but not limited to: active acne, excessive&#xD;
             skin dryness, psoriasis, eczema, rash, rosacea (particularly severe open wound stage),&#xD;
             varicella scars, open lacerations or abrasions and active cold sores or herpes sores&#xD;
             prior to treatment (duration of resolution as per the Investigator's discretion) or&#xD;
             during the treatment course.&#xD;
&#xD;
          -  History of immunosuppression/immune deficiency disorders (including HIV infection or&#xD;
             AIDS) or currently using immunosuppressive medications.&#xD;
&#xD;
          -  History of epidermal or dermal disorders (particularly if involving collagen or&#xD;
             microvascularity).&#xD;
&#xD;
          -  History of pigmentary disorders, particularly tendency for hyper- or&#xD;
             hypo-pigmentation.&#xD;
&#xD;
          -  Suffering from hormonal imbalance, as per the Investigator's discretion.&#xD;
&#xD;
          -  Having a known anticoagulative or thromboembolic condition or taking anticoagulation&#xD;
             medications one week prior to and during the treatment course (to allow inclusion,&#xD;
             temporary cessation of use as per the subject's physician discretion).&#xD;
&#xD;
          -  Having or undergoing any form of treatment for active cancer, or having a history of&#xD;
             skin cancer or any other cancer in the areas to be treated, including actinic&#xD;
             keratosis, presence of malignant or pre-malignant pigmented lesions.&#xD;
&#xD;
          -  Suffering from significant concurrent illness, such as cardiac disorders, diabetes&#xD;
             (type I or II), or pertinent neurological disorders.&#xD;
&#xD;
        Vascular lesion, tattoo or permanent make-up in the treated area.&#xD;
&#xD;
          -  Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning&#xD;
             during the study.&#xD;
&#xD;
          -  Participation in a study of another device or drug within three month prior to&#xD;
             enrollment or during the study.&#xD;
&#xD;
          -  As per the Investigator's discretion, any physical or mental condition which might&#xD;
             make it unsafe for the subject to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SouthWestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8843</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <last_update_submitted>November 28, 2014</last_update_submitted>
  <last_update_submitted_qc>November 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aesthetic dermatology</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

